These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 1563078)

  • 1. Growth hormone treatment in Turner's syndrome: short and long-term effects on metabolic parameters.
    Haeusler G; Frisch H
    Clin Endocrinol (Oxf); 1992 Mar; 36(3):247-53. PubMed ID: 1563078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone.
    Nilsson KO; Albertsson-Wikland K; Alm J; Aronson S; Gustafsson J; Hagenäs L; Häger A; Ivarsson SA; Karlberg J; Kriström B; Marcus C; Moell C; Ritzen M; Tuvemo T; Wattsgård C; Westgren U; Westphal O; Aman J
    J Clin Endocrinol Metab; 1996 Feb; 81(2):635-40. PubMed ID: 8636281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone.
    Haeusler G; Schmitt K; Blümel P; Plöchl E; Waldhör T; Frisch H
    J Clin Endocrinol Metab; 1996 Feb; 81(2):536-41. PubMed ID: 8636264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbohydrate metabolism during growth hormone treatment and after discontinuation of growth hormone treatment in girls with Turner syndrome treated with once or twice daily growth hormone injections.
    Sas T; de Muinck Keizer-Schrama S; Aanstoot HJ; Stijnen T; Drop S
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):741-7. PubMed ID: 10848879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of recombinant human growth hormone therapy on bone and clinical parameters in girls with Turner's syndrome. The Spanish Collaborative Group.
    Ferrández A; Mayayo E; Arnal JM; García C; Buñuel C; Lasarte JJ; Anton R; Puyuelo P
    Acta Paediatr Scand Suppl; 1989; 356():87-91; discussion 92. PubMed ID: 2816362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner's syndrome, with important modulations by treatment with 17 beta-estradiol.
    Gravholt CH; Naeraa RW; Fisker S; Christiansen JS
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2570-7. PubMed ID: 9253336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of spontaneous or induced puberty on the growth promoting effect of treatment with growth hormone in girls with Turner's syndrome.
    Massa G; Maes M; Heinrichs C; Vandeweghe M; Craen M; Vanderschueren-Lodeweyckx M
    Clin Endocrinol (Oxf); 1993 Mar; 38(3):253-60. PubMed ID: 8458097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of growth hormone administration frequency on 24-hour growth hormone profiles and levels of other growth related parameters in girls with Turner's syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A; de Muinck Keizer-Schrama SM; Stijnen T; Mouton JW; Blum WF; Mercado M; Baumann G; Drop SL
    Clin Endocrinol (Oxf); 1993 Jul; 39(1):77-84. PubMed ID: 7688672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slow baseline growth and a good response to growth hormone (GH) therapy are related to elevated spontaneous GH pulse frequency in girls with Turner's syndrome.
    Kamp GA; Kuilboer MM; Wynne HJ; Rongen-Westerlaken C; Johnson ML; Veldhuis JD; Wit JM
    J Clin Endocrinol Metab; 1993 Jun; 76(6):1604-9. PubMed ID: 8501169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum growth hormone (GH)-binding protein and insulin-like growth factor-I levels in Turner's syndrome before and during treatment with recombinant human GH and ethinyl estradiol.
    Massa G; Bouillon R; Vanderschueren-Lodeweyckx M
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1298-302. PubMed ID: 1430092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone therapy in Turner's syndrome: an update on final height. Genentech National Cooperative Study Group.
    Rosenfeld RG
    Acta Paediatr Suppl; 1992 Sep; 383():3-6; discussion 7. PubMed ID: 1458013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone secretion in Turner's syndrome and influence of oxandrolone and ethinyl oestradiol.
    Massarano AA; Brook CG; Hindmarsh PC; Pringle PJ; Teale JD; Stanhope R; Preece MA
    Arch Dis Child; 1989 Apr; 64(4):587-92. PubMed ID: 2751332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final height in girls with Turner's syndrome treated with once or twice daily growth hormone injections. Dutch Advisory Group on Growth Hormone.
    Sas TC; de Muinck Keizer-Schrama SM; Stijnen T; van Teunenbroek A; Hokken-Koelega AC; Waelkens JJ; Massa GG; Vulsma T; Gerver WJ; Reeser HM; Delemarre-van de Waal HE; Jansen M; Drop SL
    Arch Dis Child; 1999 Jan; 80(1):36-41. PubMed ID: 10325756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased sensitivity to insulin-like growth factor I in Turner's syndrome: a study of monocytes and T lymphocytes.
    Hochberg Z; Aviram M; Rubin D; Pollack S
    Eur J Clin Invest; 1997 Jul; 27(7):543-7. PubMed ID: 9263738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of short term treatment with growth hormone and ethinyl estradiol on lower leg growth rate in girls with Turner's syndrome.
    Ross JL; Cassorla F; Carpenter G; Long LM; Royster MS; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1988 Sep; 67(3):515-8. PubMed ID: 3410937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma growth hormone-binding protein activity, insulin-like growth factor I, and its binding protein levels in patients with Turner's syndrome: effect of short- and long-term recombinant human growth hormone administration.
    Saggese G; Federico G; Cinquanta L
    Pediatr Res; 1995 Jan; 37(1):106-11. PubMed ID: 7535419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulsatile growth hormone release in Turner's syndrome and short normal children.
    Ghizzoni L; Lamborghini A; Ziveri M; Volta C; Panza C; Balestrazzi P; Bernasconi S
    Acta Endocrinol (Copenh); 1990 Sep; 123(3):291-7. PubMed ID: 2239077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth-promoting effect of growth hormone and low dose ethinyl estradiol in girls with Turner's syndrome.
    Vanderschueren-Lodeweyckx M; Massa G; Maes M; Craen M; van Vliet G; Heinrichs C; Malvaux P
    J Clin Endocrinol Metab; 1990 Jan; 70(1):122-6. PubMed ID: 2294126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations.
    Haeusler G; Frisch H; Schmitt K; Blümel P; Plöchl E; Zachmann M; Waldhör T
    Eur J Pediatr; 1995 Jun; 154(6):437-44. PubMed ID: 7545577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final height of patients with Turner's syndrome treated with growth hormone (GH): indications for GH therapy alone at high doses and late estrogen therapy. Italian Study Group for Turner Syndrome.
    Cacciari E; Mazzanti L
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4510-5. PubMed ID: 10599710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.